SB L1 - Monoamines 3 - New treatments

Question 1

Desvenlafaxine succinate

Answer 1

SNRI – primary metabolite of venlafaxine – affects 5HTT>NAT

Question 2

Trazodone extended release

Answer 2

SSRI + 5HT2a/5HT2c antagonist

Question 3

Vilazodone

Answer 3

SSRI with 5HT1A receptor partial agonist actions, or a serotonin partial agonist reuptake inhibitor (SPARI)

Question 4

Agomelatine

Answer 4

A melatonin agonist + 5HT2c antagonist (like mirtazapine)

• synergistic effects

Question 5

Efficacy of Vilazodone

2 refs

Answer 5

Two short-term (8wk) Phase III double blind randomised outpatient clinical trials support the efficacy of vilazodone vs. placebo for adults with MDD (Rickels et al. 2009; Khan et al. 2011)

Question 6

Synergisitc effects of agomelatine

Answer 6

Improve quality of sleep
Preserved sexual function
Anxiolytic properties
Antidepressant properties

Question 7

Efficacy of agomelatine

ref

Answer 7

Agomelatine: better at relapse prevention, better tolerated, faster onset

De Bodinat et al. 2010